Compare SAFE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAFE | NVAX |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.6B |
| IPO Year | 1999 | 1996 |
| Metric | SAFE | NVAX |
|---|---|---|
| Price | $13.49 | $8.16 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 9 |
| Target Price | ★ $18.82 | $11.33 |
| AVG Volume (30 Days) | 254.4K | ★ 3.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | 7.43 | ★ 309.76 |
| EPS | 1.59 | ★ 2.58 |
| Revenue | $385,552,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $8.50 | ★ $3.16 |
| Revenue Growth | 5.43 | ★ 64.69 |
| 52 Week Low | $12.76 | $5.01 |
| 52 Week High | $18.61 | $11.85 |
| Indicator | SAFE | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 36.25 |
| Support Level | $13.48 | $8.01 |
| Resistance Level | $14.29 | $8.45 |
| Average True Range (ATR) | 0.40 | 0.54 |
| MACD | -0.11 | -0.27 |
| Stochastic Oscillator | 8.19 | 14.73 |
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.